Valuation: Thiogenesis Therapeutics, Corp.

Market Cap 43.39M 30.91M 27.74M 25.64M 23.22M 2.94B 43.91M 307M 122M 1.54B 116M 114M 4.89B P/E 2024
-8.65x
P/E 2025 -4.25x
Enterprise Value 41.77M 29.76M 26.7M 24.69M 22.36M 2.83B 42.28M 295M 118M 1.48B 112M 109M 4.71B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.84%
Yield 2024 *
-
Yield 2025 -
1 day+1.61%
1 week+29.90%
Current month+28.57%
1 month+28.57%
3 months+10.53%
6 months+18.87%
Current year-3.08%
1 week 0.52
Extreme 0.52
0.64
1 month 0.48
Extreme 0.48
0.64
Current year 0.44
Extreme 0.44
0.66
1 year 0.44
Extreme 0.44
0.81
3 years 0.44
Extreme 0.44
1.06
5 years 0.38
Extreme 0.375
1.06
10 years 0.38
Extreme 0.375
1.06
Manager TitleAgeSince
Chief Executive Officer 75 31/03/2022
Chief Executive Officer 60 -
Director TitleAgeSince
Director/Board Member 63 31/03/2022
Chairman 73 31/03/2022
Director/Board Member 60 03/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
29/9/26 Buy

Chief Financial Officer

50,000 0.0714%
22/9/26
Rosalind Advisors, Inc.
BuyCompany 249,500 0.3565%
17/9/26 Option

Director

200,000 0.2858%
Change 5-day change 1-year change 3-year change Capi.($)
+1.61%+29.90%-5.97%-23.17% 30.89M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.08%+0.16%+27.02%+56.40% 44.75B
+2.32%-2.97%+18.35%+100.95% 41.62B
+0.12%-3.59%+222.01%+920.79% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.09%+1.55%+46.03%+143.66% 38.05B
Weighted average by Cap. +3.05%-0.29%+47.24%+160.86%

Financials

2024 2025
Net sales - -
Net income -3.15M -2.24M -2.01M -1.86M -1.68M -213M -3.18M -22.23M -8.85M -112M -8.41M -8.23M -355M -7.43M -5.29M -4.75M -4.39M -3.97M -504M -7.52M -52.47M -20.9M -264M -19.86M -19.44M -837M
Net Debt -3.85M -2.74M -2.46M -2.27M -2.06M -261M -3.89M -27.19M -10.83M -137M -10.29M -10.07M -434M -1.62M -1.15M -1.03M -955K -865K -110M -1.64M -11.42M -4.55M -57.38M -4.32M -4.23M -182M
Projected Income Statement - Annual - Thiogenesis Therapeutics, Corp.
Logo Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.
Employees
-
Date Price Change Volume
28/10/26 CA$0.6300 +1.61% 500
27/10/26 CA$0.6200 -3.13% 51,500
26/10/26 CA$0.6400 +3.23% 130,566
23/10/26 CA$0.6200 +5.08% 28,000
22/10/26 CA$0.5900 +21.65% 129,000

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Thiogenesis Therapeutics, Corp.